Recent Advances in Pulmonary Inhalation of Nanoformulations
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".
Deadline for manuscript submissions: 31 August 2024 | Viewed by 1489
Special Issue Editors
Interests: inhalable nanomedicines; drug delivery; ferroptosis; protein corona; biological fate
Special Issues, Collections and Topics in MDPI journals
Interests: nano drug delivery system; biomimetic drug delivery system; lung cancer therapy
Interests: cell therapy; bioinspired and biomimetic design; inhalable biomaterials
Special Issue Information
Dear Colleagues,
With the long-term development of nanoscience and nanotechnology, nanoformulations (to name a few, liposomes, solid lipid nanoparticles, polymeric micelles, metal-organic frameworks, exosomes, biomimetic nanoparticles, etc.) of versatile functions have widely been considered as promising therapeutics for various diseases. Since the new millennium, respiratory system diseases with growing mortality and morbidity impose severe burden on the patients and the society. They include: (1) Obstructive diseases, like asthma and chronic obstructive pulmonary disease (COPD); (2) Fibrotic diseases, like cystic fibrosis (CF) and idiopathic pulmonary fibrosis (IPF); (3) Infectious diseases, like severe acute respiratory syndrome (SARS) and corona virus disease 2019 (COVID-19); (4) Neoplastic diseases, like small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Triggered by the clinical demand and aiming to manage and combat respiratory system diseases, the scientific community exploits the feasibility of using nanoformulations as innovative therapeutics. As the major lesion sites of these diseases locate in the respiratory system, pulmonary inhalation that can achieve a high accumulation in the respiratory tract will be a potent delivery route for the nanoformulations. Based on this rationale, a series of inhalable nanoformulations have been developed. We believe that through comprehensive investigation, the clinical translation of relevant systems can be anticipated, which ultimately alleviates the medical burdens of respiratory system diseases. The aim of this Special Issue is to highlight new developments in the field of pulmonary inhalation of nanoformulations intended for respiratory system disease treatment. All kinds of nanoformulations suitable for pulmonary delivery can be involved, e.g., liposomes, solid lipid nanoparticles, polymeric micelles, metal-organic frameworks, exosomes and biomimetic nanoparticles. The cargoes for these nanoformulations can be both small and large molecules. It is imagined that they are administrated to obstructive, fibrotic, infectious or neoplastic disease models. We would like to invite high-quality original researches and review papers dealing with abovementioned aspects. We particularly welcome those contributions with industrialization or translation focuses.
Dr. Zhengwei Huang
Dr. Tianqun Lang
Prof. Dr. Ling Guo
Dr. Yixuan Wang
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pulmonary delivery
- nanomedicines for inhalation
- inhalable nanovaccines
- nanoformulation design
- respiratory system disease therapeutics
